5108-96-3
5108-96-3 结构式
基本信息
吡咯烷二硫代氨基甲酸铵
1-吡咯烷硫代羧酸铵盐
吡咯二硫代甲酸铵
吡咯烷二硫代甲酸铵
四次甲基二硫代氨基甲酸铵
四亚甲基二硫代氨基甲酸铵
1-吡咯烷硫代羧酸铵盐/吡咯二硫代甲酸铵
1-吡咯烷羰基二硫酸铵盐
吡咯烷二硫代甲酸铵盐
1-吡咯烷硫代氨基甲酸铵盐
1-PYRROLIDINECARBODITHIOIC ACID, AMMONIUM SALT
1-PYRROLIDINEDITHIOCARBOXYLIC ACID, AMMONIUM SALT
AMMONIUM 1-PYRROLIDINECARBODITHIOATE
AMMONIUM 1-PYRROLIDINEDITHIOCARBAMATE
AMMONIUM PYRROLIDINECARBODITHIOATE
AMMONIUM PYRROLIDINEDITHIOCARBAMATE
AMMONIUM PYRROLIDINEDITHIOCARBAMATE AMMONIUM SALT
AMMONIUM PYRROLIDINE DITHIOFORMATE
AMMONIUM PYRROLIDINE-N-DITHIOCARBAMATE
AMMONIUM PYRROLIDINO-DITHIOCARBAMATE
AMMONIUM PYRROLIDINODITHIOCARBOXYLATE
AMMONIUM TETRAMETHYLENE DITHIOCARBAMATE
APCD
APDC
APDC AMMONIUM SALT
APDTC
APDTC AMMONIUM SALT
N,N-TETRAMETHYLENEDITHIOCARBAMIC ACID AMMONIUM SALT
PDTC, NH4
物理化学性质
安全数据
应用领域
常见问题列表
| Target | Value |
|
NF-κB
() |
Pretreatment of cells with Pyrrolidinedithiocarbamate ammonium (Ammonium pyrrolidinedithiocarbamate; 3-1000 μM) dose-dependently attenuate IL-8 production.
Furthermore, pyrrolidinedithiocarbamate ammonium (100 μM) suppresses the accumulation of IL-8 mRNA.
Pyrrolidinedithiocarbamate ammonium inhibits the activation of NF-κB, because it suppresses both NF-κB DNA binding and NF-κB-dependent transcriptional activity. NF-κB inhibition with pyrrolidinedithiocarbamate ammonium decrease IL-8 production by intestinal epithelial cells.
The DSS+pyrrolidinedithiocarbamate ammonium-treated groupII exhibits suppression of shortening of intestinal length and reduction of DAI score. Activated NF-κB level and IL-1β and TNF-α levels are significantly lower in DSS+pyrrolidinedithiocarbamate ammonium-treated groupII. These findings suggest that suppression of NF-κB activity by pyrrolidinedithiocarbamate ammonium can delay the healing of mucosal tissue defects (erosions or ulcers) arising from inflammation, but that it can strongly suppress the expression of inf-lammatory cytokines (IL-1β and TNF-α), resulting in significant alleviation of colitis. pyrrolidinedithiocarbamate ammonium is useful for the treatment of ulcerative colitis.